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AbsTRACT
This review focuses on the available data regarding the 
utility of advanced left ventricular (LV) imaging in aortic 
stenosis (AS) and its potential impact for optimising 
the timing of aortic valve replacement. Ejection fraction 
is currently the only LV parameter recommended to 
guide intervention in AS. The cut- off value of 50%, 
recommended for decision- making in asymptomatic 
patients with AS, is currently under debate. Several 
imaging parameters have emerged as predictors of 
disease progression and clinical outcomes in this 
setting. Global longitudinal LV strain by speckle tracking 
echocardiography is useful for risk stratification of 
asymptomatic patients with severe AS and preserved LV 
ejection fraction. Its prognostic value was demonstrated 
in these patients, but further work is required to define 
the best thresholds to aid the decision- making process. 
The assessment of myocardial fibrosis is the most 
studied application of cardiac magnetic resonance 
in AS. The detection of replacement fibrosis by late 
gadolinium enhancement offers incremental prognostic 
information in these patients. Clinical implementation 
of this technique to optimise the timing of aortic valve 
intervention in asymptomatic patients is currently tested 
in a randomised trial. The use of T1 mapping techniques 
can provide an assessment of interstitial myocardial 
fibrosis and represents an expanding field of interest. 
However, convincing data in patients with AS is still 
lacking. All these imaging parameters have substantial 
potential to influence the management decision in 
patients with AS in the future, but data from randomised 
clinical trials are awaited to define their utility in daily 
practice.
InTRoduCTIon
Aortic stenosis (AS) is the most common valvular 
heart disease in adults, with an increasing prev-
alence in the ageing population.1 Calcific AS is a 
complex disease that includes changes in the valve 
and myocardium.2 The response of the left ventricle 
(LV) to pressure overload in AS ultimately contrib-
utes to symptom occurrence, and its consequences 
impact management and outcomes.
Over the last decade, research related to LV struc-
ture and function in patients with AS has increased, 
due to improvements in imaging modalities and 
potential therapies, in particular the emergence 
of transcatheter aortic valve implantation (TAVI). 
This has prompted focus on subclinical changes in 
LV function, as well as the degree of reversibility of 
LV structural changes in advanced stages of AS—
factors which may influence the optimal timing of 
valve intervention.
In this review, we summarise the available 
data on the role of advanced LV imaging in AS, 
focusing on the pathophysiological insights that 
they provide and their potential impact on clinical 
decision- making.
LV response to As
In patients with significant AS, pressure overload 
causes an increase in LV wall stress that stimulates 
myocyte enlargement and increases in LV wall 
thickness. Concentric hypertrophy is the primary 
compensatory mechanism that leads to increased 
contractile force and reduced systolic wall stress.3
The magnitude of LV hypertrophy (LVH) is 
poorly linked to AS severity4 suggesting that other 
determinants are also involved in its development. 
Age, gender, angiotensin- converting enzyme I/D 
polymorphism, co- existing coronary artery disease 
and hypertension are additional factors influencing 
the LV response to AS.5 6 Reduced systemic arterial 
compliance independently contributes to increased 
afterload and may influence LV remodelling.7
Women exhibit different patterns of LV remodel-
ling, less LVH, and a lower degree of focal fibrosis 
and extracellular expansion compared with men 
with similar AS severity, age and functional status.8
Although beneficial initially, ultimately the hyper-
trophic response can decompensate, with patients 
transitioning to heart failure, symptoms and 
adverse events (figure 1). Myocyte degeneration, 
cell death and fibrosis have been described as the 
key structural changes responsible for this transi-
tion.9 Increased myocardial oxygen demand, unbal-
anced by an insufficient increase in the coronary 
capillary network, is thought to lead to impaired 
coronary flow reserve and myocardial perfusion, 
with increased cardiomyocyte cell death.10 More-
over, myocardial supply can also be reduced as a 
result of decreased coronary perfusion pressure, 
due to the presence of AS.11
Histopathological studies have shown that 
myocardial fibrosis in particular is an integral 
part of myocardial disease progression in AS.12 
The mechanisms governing the development and 
progression of myocardial fibrosis are incom-
pletely understood. An imbalance in matrix 
metalloproteinases and tissue inhibitors of matrix 
metalloproteinase activity, alongside increases in 
angiotensin- converting enzyme and transforming 
growth factor beta1 activity contribute to the 
development of fibrosis,13 14 and each of these 
mechanisms could be a potential target for inter-
ventions. Myocardial fibrosis has traditionally 
been categorised into diffuse interstitial fibrosis 
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Figure 1 Consequences of very severe calcific aortic stenosis (A) in a patient in their 60s without a history of systemic hypertension. Peak 
transvalvular gradient was 127 mm Hg (mean gradient of 84 mm Hg) (B) at a blood pressure of 120/70 mm Hg, with an estimated LV systolic pressure 
of 247 mm Hg and a calculated aortic valve area of 0.6 cm2. As a result of severe pressure overload, there was significant concentric LV hypertrophy 
(A) with an indexed LV mass of 130 g/m2 and a relative wall thickness of 0.55. Global systolic LV function was preserved (ejection fraction of 65%) 
while systolic myocardial velocities measured by tissue Doppler imaging were significantly reduced (septal s’ 5.2 cm/s)(D), indicating LV longitudinal 
dysfunction. There was significant LV diastolic dysfunction: impaired relaxation with a septal e’ of 4.8 cm/s (D) and increased filling pressure—
pseudonormal mitral inflow (C) with elevated E/e' ratio of 16 and a moderately dilated left atrium. LV, left ventricular.
and replacement fibrosis. Interstitial fibrosis occurs earlier in 
the disease process and appears to be reversible with afterload 
relief. Replacement fibrosis is the result of myocyte necrosis 
and replacement of these cells with extracellular matrix. This 
typically occurs in a non- infarct distribution and is largely irre-
versible. However, recent elegant histological work utilising 
myocardial biopsies and cardiac magnetic resonance (CMR) has 
shed further light on the complexities of myocardial fibrosis in 
AS, demonstrating frequent overlap in these forms of fibrosis 
and that a gradient exists in myocardial fibrosis extending from 
the sub- endocardium to the mid- myocardium.15
Echocardiography in the assessment of the LV in As
Echocardiography is the first- line imaging modality to evaluate 
patients with AS. An accurate and precise assessment of both 
LV remodelling and function is warranted in all patients with 
AS. Moreover, echocardiography allows assessment of structural 
and functional changes in the atria and the right ventricle, with a 
stepwise increase in mortality observed with progressive cardiac 
damage.2
LV remodelling
Linear LV dimensions must be measured to estimate LV mass and 
relative wall thickness, for LV remodelling classification.16 LVH 
is estimated based on conventional two- dimensional (2D) echo-
cardiography measurements of wall thickness in the septum and 
inferolateral wall.16 The three- dimensional (3D) echocardiog-
raphy assessment of LV mass, validated against CMR, overcomes 
the geometrical assumptions inherent in 2D echocardiography, 
with improved accuracy.17 However, the lack of specific cut- off 
values currently hampers its widespread clinical use.
LV diastolic function
LV diastolic dysfunction is one of the earliest consequences of 
LVH and myocardial fibrosis in AS. Although LV diastolic func-
tion is a sensitive marker of myocardial changes, it lacks speci-
ficity and does not play a role in timing intervention for patients 
with AS. LV diastolic dysfunction is associated with increased 
mortality, worsens with progressive myocardial remodelling 
before aortic valve replacement (AVR), and gradually improves 
with reverse remodelling after AVR.18 The improvement of LV 
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Figure 2 LV global longitudinal strain measured by speckle tracking echocardiography in a patient with severe aortic stenosis before (A) and 
1 month after TAVI (B). Before TAVI, the LVEF was 30% and the mean transvalvular gradient was 70 mm Hg. The GLS was severely reduced: −5.7%. 
Systolic lengthening is present in the basal and mid- segments of the lateral wall. Angiography revealed no significant coronary artery disease. One 
month after TAVI, LVEF increased to 55% while GLS significantly improved: −13.3%. GLS, global longitudinal strain; LV, left ventricle; LVEF, LV ejection 
fraction; TAVI, transcatheter aortic valve implantation.
diastolic dysfunction in AS takes longer than the reversal of LV 
systolic dysfunction since the former is mainly related to long- 
standing LV structural changes while the latter also reflects after-
load mismatch.19 20
LV systolic function
The assessment of LV systolic performance begins with measuring 
LV ejection fraction (LVEF).21 The recommended 2D echocar-
diography method is the biplane method of discs.16 Whenever 
feasible, the measurement of LVEF by 3D echocardiography is 
recommended.16
Although LVEF carries important prognostic information and 
guides therapy, it is load- dependent and not an index of myocar-
dial contractility. LVEF is also often confounded in severe AS by 
the presence of LVH,22 and remains in the normal range until 
late in the disease course, even when myocardial fibrosis and 
longitudinal dysfunction are already present.23
Assessment of LV deformation detects earlier changes in 
myocardial function and allows a better understanding of 
progression to heart failure in AS.24–26 Systolic longitudinal 
strain parameters, assessed by tissue Doppler imaging (TDI), are 
significantly decreased in patients with AS and preserved LVEF 
and their decline is related to AS severity.25 These parameters 
improve rapidly after AVR, preceding any substantial changes in 
LV mass and EF, and suggesting their partial dependence on LV 
afterload.25 26
However, the assessment of LV deformation by TDI requires 
parallel alignment of the Doppler beam with myocardial motion 
direction and cannot be performed for all the LV segments.
Speckle- tracking echocardiography (STE) overcomes these 
limitations, allowing a multidirectional evaluation of myocar-
dial deformation.27 In AS, LV longitudinal strain is impaired, 
especially in the basal segments, and is a predictor of clinical 
events in asymptomatic AS (figure 2).24 28 The primary mecha-
nism involved in the alteration of LV longitudinal strain in AS is 
the development of LV fibrosis: both related to the valve disease 
and prior myocardial infarction.23 Moreover, global longitudinal 
strain (GLS) also depends on the pattern of LV remodelling, with 
lower values in patients with significant concentric LVH.29 An 
increasing body of evidence suggests the usefulness of GLS for 
risk stratification and management of asymptomatic patients 
with severe AS and preserved LVEF.24 Recent studies have shown 
that GLS predicts postoperative LV dysfunction and outcomes 
better than EF.30 GLS improves early after AVR,31 reflecting its 
relationship to afterload mismatch as well as fibrosis, although 
this area requires further study.
A progressive transmural impairment of myocardial func-
tion, with a gradual decrease in circumferential and radial 
deformation, was demonstrated with increasing afterload in 
AS.32
Mechanical dispersion measured by STE reflects LV mechan-
ical dyssynchrony and has been linked to myocardial fibrosis 
and ventricular arrhythmias in myocardial infarction and 
cardiomyopathies.33 34 Increased LV mechanical dispersion is 
associated with adverse outcome in patients with AS, inde-
pendently of LVEF, flow status or treatment.35 Mechanical 
dispersion appears to be less afterload dependent than LVEF 
and GLS, and may provide novel prognostic information in AS 
(figure 3).
CMR imaging
The role of CMR has burgeoned in recent years, largely due to 
advances in scanner technology, software and accessibility. CMR 
offers the distinct advantage of combining multiparametric 
assessments of anatomy, function with detailed soft tissue char-
acterisation. Indeed, its ability to identify, quantify and discrim-
inate between myocardial diseases is superior to other currently 
available imaging modalities. This is of importance in AS, where 
an understanding of myocardial health and function may be of 
clinical relevance, beyond standard measures of valve haemo-
dynamics and obstruction. Currently, the use of CMR to detect 
myocardial fibrosis is the most studied application of myocardial 
tissue characterisation in AS.
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Figure 3 LV mechanical dispersion assessed by speckle- tracking echocardiography in the four- chamber view in two patients with severe aortic 
stenosis and preserved LV ejection fraction. White horizontal arrows indicate contraction duration, defined as the time from QRS onset on the 
ECG to peak negative longitudinal strain. Mechanical dispersion is defined as the SD of contraction duration from all LV segments. (A) Low value 
of mechanical dispersion indicating a homogeneous contraction pattern. (B) Pronounced mechanical dispersion in a patient with significant LV 
hypertrophy and complex ventricular arrythmia. LV: Left ventricular.
Replacement fibrosis: late gadolinium enhancement
Replacement fibrosis is detected with CMR using late gado-
linium enhancement (LGE). Gadolinium- based contrast agents 
partition into extracellular space and wash out of areas of focal 
fibrosis slower than healthy tissue. This provides a clear visual 
contrast between focal extracellular matrix expansion and 
healthy myocardium which can also be quantified (figure 4).
LGE has been studied in various myocardial pathologies and is 
universally associated with an increased risk of adverse outcome. 
A large body of observational data has demonstrated this same 
association in AS.4 36–39 Indeed, multiple studies have consis-
tently shown strong independent associations between ischaemic 
and non- ischaemic LGE and both cardiovascular and all- cause 
mortality. Furthermore, the development of non- ischaemic LGE 
in AS appears to serve as an objective marker of LV decompensa-
tion and portends further rapid progression of fibrosis burden.40 
Importantly, this fibrosis does not regress after AVR15 40 the 
burden of scarring that develops while awaiting surgery persists 
in patients for life. This is important because the more myocar-
dial fibrosis, the worse the long- term prognosis.38 The detection 
of LGE in AS may therefore offer incremental prognostic infor-
mation. Clinical implementation of LGE to optimise the timing 
of aortic valve intervention is being tested in the randomised 
Early Valve Replacement Guided by Biomarkers of LV Decom-
pensation in Asymptomatic Patients with Severe AS trial.41
diffuse interstitial fibrosis: T1 mapping
Unlike LGE, which is insensitive for the detection of diffuse 
interstitial fibrosis, T1 mapping techniques can provide overall 
assessments of the extracellular compartment. While providing a 
close surrogate assessment of myocardial fibrosis,42 these markers 
are also affected by other extracellular factors including oedema 
and capillary volume. The most studied methods are native T1, 
which does not require gadolinium contrast, and extracellular 
volume fraction (ECV%).43 Native T1 provides myocardial 
T1 times which can vary depending on the type of myocardial 
pathology present, while ECV% provides an estimate of the 
ECV expressed as a fraction of total myocardial volume. These 
parameters have prognostic significance across a range of cardio-
myopathies and have been the focus of substantial research to 
define normal values and to develop sequences that can be 
applied across different scanners. The indexed ECV (or matrix 
volume) has also been studied in AS; this measure provides an 
estimate of absolute ECV (ECV × LV myocardial volume) and 
therefore the total burden of myocardial fibrosis. T1 mapping 
has provided important insight into the myocardium in AS, most 
notably the potential for diffuse fibrosis to reverse post- AVR, 
with an increasing body evidence demonstrating its prognostic 
power in AS as with other conditions.4 44
The role of different LV imaging parameters in patients with 
AS is presented in table 1.
other diagnostic modalities
Recent data have demonstrated the potential of CT for both 
tissue characterisation and deformation assessments. Specifi-
cally, small studies have shown that CT- derived ECV% correlates 
with CMR- derived ECV% as well as histology,45 46 while CT- de-
rived GLS also appears to be feasible in selected patients with 
good image quality.47 Interestingly, CT- derived GLS correlated 
well with CT- derived ejection fraction, but only modestly with 
echocardiography- derived GLS. These advances are of partic-
ular interest given the routine use of CT for planning TAVI and 
may improve risk prediction.48 Additionally, the detection of a 
very high ECV% in this context is potentially important due to 
the relatively high prevalence of cardiac amyloid in this patient 
population.49 Finally, there is also interest in applying advanced 
molecular imaging techniques to interrogate myocardial disease 
activity in addition to the structural and functional assessments 
provided by current modalities. In particular, positron emission 
tomography using radiotracers to detect fibrosis activity holds 
major promise in different disease settings, including AS.
The imaging data must be integrated with clinical data and 
other information. Strain pattern on 12- lead ECG has a high 
specificity (but low sensitivity) for LVH and provides prognostic 
information.50 Increased levels of BNP and troponins are asso-
ciated with LVH, fibrosis and a worse prognosis.w1–w3 However, 
these biomarkers are not specific to AS; therefore, a combined 
imaging- biomarker approach may work best.
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Figure 4 LGE on CMR imaging. Panels A and B are short axis and three- chamber views of a patient with aortic stenosis. The red arrows indicate 
focal, non- ischaemic (mid- wall) LGE in the basal inferolateral wall. The dotted blue arrow in panel A indicates the left ventricular outflow tract, 
where caution must be taken in interpreting contrast enhancement due to partial volume effects. in contrast, panels C and D are the same views of a 
different patient with a myocardial infarction involving the same segments (orange arrows). Note the transmural pattern and wall thinning. LGE, Late 
gadolinium enhancement; CMR, cardiac magnetic resonance.
Implications of recent imaging advances in different clinical 
scenarios in As
Asymptomatic severe AS
In physically active patients, an exercise test is recommended to 
reveal symptoms or a fall in blood pressure.21 Ejection fraction 
is the only LV parameter currently recommended to guide inter-
vention in asymptomatic patients with AS, with a cut- off value 
of <50% for referral to AVR.21 The usefulness of LVEF in this 
setting is questioned, as few patients with severe AS and LVEF 
<50% are asymptomaticw4 and there are no robust outcome 
data to support this threshold. Furthermore, the cut- off value 
of <50% is problematic since in asymptomatic patients there is 
evidence that LVEF <55% correlates with excess mortality in 
medically managed patients and is an independent determinant 
of poorer survival after surgical AVR.w5
The assessment of GLS could be more appropriate to detect 
subclinical LV dysfunction in this setting. An individual partici-
pant data meta- analysis24 including 1067 asymptomatic patients 
with significant AS and LVEF >50%, confirmed that GLS is 
strongly associated with mortality, with >2.5 fold increase in 
risk of death in patients with GLS<14.7% while patients with 
GLS>18% had an excellent outcome. These data support the 
systematic measurement of GLS in asymptomatic patients with 
AS and preserved LVEF and may promote its use in clinical prac-
tice. Future trials to establish clear thresholds and incorporating 
GLS into decision- making for asymptomatic patients with AS 
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Table 1 Role of imaging techniques in assessing the left ventricle in 
patients with aortic stenosis
Advantages disadvantages
Echocardiography
  LV mass and 
RWT
 ► Easy to access
 ► Useful for classification of LV 
remodelling
 ► Prognostic value
 ► Less accurate and 
reproducible estimation of 
LV mass compared with 
CMR
  LV ejection 
fraction
 ► Mandatory in the decision- 
making process
 ► Established prognostic value 
in AS
 ► Difficult to measure in 
patients with suboptimal 
acoustic window
 ► Unable to detect early LV 
dysfunction
  Myocardial 
velocities, 
strain ad 
strain rate (TDI 
derived)
 ► Early markers of LV dysfunction 
especially when assessed 
during or after exercise in 
asymptomatic patients with AS
 ► Angle dependent
 ► Do not reflect global LV 
function in patients with 
segmental wall motion 
abnormalities
 ► Partial dependence on the 
LV afterload
  Global 
longitudinal 
strain (STE)
 ► Detects global LV dysfunction
 ► An early marker or LV 
decompensation
 ► Prognostic value in AS
 ► Inter- vendor variability
 ► Lack of clear thresholds to 
determine LV dysfunction
CMR imaging
  LGE  ► Robust observational prognostic 
data
 ► Qualitative as well as 
quantitative assessment is of 
value
 ► Access to CMR
 ► Use of gadolinium contrast
 ► Unable to detect early, 
reversible interstitial fibrosis
 
  Native T1  ► No requirement for gadolinium 
contrast
 ► Global assessment of 
myocardial tissue composition
 ► Early assessment of reversible 
fibrosis
 ► Access to CMR
 ► Lack of established cut- offs 
for normal and disease 
states
 
  ECV%  ►  Differentiates between 
intracellular and extracellular 
components of myocardium
 ►  Dynamic pre- AVR and 
post- AVR
 ►  Early assessment of reversible 
fibrosis
 ►  Access to CMR
 ►  Use of gadolinium 
contrast
 
Cardiac CT
  ECV  ►  Moderate correlation with 
collagen volume fraction and 
CMR ECV%
 ►  Potentially no requirement for 
blood sampling (synthetic ECV)
 ►  Integration into routine TAVI 
workflow
 ►  Iodinated contrast
 ►  Ionising radiation
  GLS  ►  Good correlation with CT- 
derived ejection fraction
 ►  Moderate correlation with 
echocardiography- derived GLS
 ►  Potential prognostic relevance
 ►  Iodinated contrast
 ►  Ionising radiation
 ►  Multiphase acquisition
 ►  Adequate image quality 
required
AS, aortic stenosis; AVR, aortic valve replacement; CMR, cardiac magnetic resonance; 
ECV%, extracellular volume fraction; GLS, global longitudinal strain; LGE, late gadolinium 
enhancement; LV, left ventricular; RWT, relative wall thickness; STE, speckle tracking 
echocardiography; TAVI, transcatheter aortic valve implantation; TDI, tissue Doppler imaging.
will be required to establish its role as a marker of subclinical 
LV decompensation. Moreover, careful attention should be paid 
to whether markers of LV dysfunction relate to the valve disease 
itself or other comorbidities, an area where CMR currently 
holds an advantage.
Low-flow low-gradient As with reduced LVEF
In these patients, it is important to consider the mechanism 
of LVEF reduction and whether it is reversible or not. Exten-
sive myocardial infarction or cardiomyopathy may hamper the 
recovery of LV function after AVR due to irreversible scar.
In a small CMR study, patients with classical low- flow low- 
gradient AS had significantly more replacement fibrosis and an 
increased burden of interstitial fibrosis compared with patients 
with high- gradient AS.w6
Dobutamine stress echocardiography has been widely used to 
identify the presence of LV flow reserve, traditionally regarded 
as a predictor of outcome in these patients.w7 However, although 
the absence of contractile reserve is related to a high operative 
mortality after surgical AVR, it does not predict the absence of 
LVEF recovery after AVR.w8 Lack of LV contractile reserve had 
no effect on clinical outcomes or changes in LVEF in patients 
with low- flow low- gradient AS undergoing TAVI.w9 As such, the 
absence of flow reserve should not be considered a contraindi-
cation to AVR in patients with confirmed low- flow low- gradient 
severe AS.21
Longitudinal LV strain parameters were independent predic-
tors of survival in patients with low- flow low- gradient AS, partic-
ularly in those treated conservatively.w10 Stress GLS provides 
significant incremental prognostic value compared with resting 
GLS, but its feasibility is lower.
Low-flow low-gradient As with preserved LVEF
In this challenging setting, several parameters of LV geometry 
and function are used to identify patients with increased likeli-
hood of severe AS: the degree of LVH, reduced LV longitudinal 
function without other explanation and low LV stroke volume.21
A reduced stroke volume can reflect a small LV cavity due 
to excessive LVH, with a high relative wall thickness.w11 The 
decrease in stroke volume is accentuated by reduced LVEF 
within the normal range.w11 In several studies, LV stroke volume 
was an independent predictor of survival, more powerful than 
LVEF.w12,w13
An association between concentric remodelling and restric-
tive filling was observed in these patients, probably reflecting 
the increased LV stiffness caused by a higher degree of myocar-
dial fibrosis.w11 Echocardiographic assessments of mitral annular 
displacement and GLS are useful to detect reduced LV longitu-
dinal function related to fibrosis confirmed on CMR.23
Concomitant presence of severe mitral or tricuspid regurgi-
tation, atrial fibrillation, LV dyssynchrony and right ventricular 
dysfunction can also contribute to low- flow states and need to be 
identified for optimal management.21
A prevalence of 6%–16% of wild- type transthyretin cardiac 
amyloidosis was reported in patients with severe AS.w14,w15 
Regional variations in longitudinal LV strain from base to apex 
with a relative ‘apical sparing’ pattern was suggested to differen-
tiate cardiac amyloidosis from other causes of LVH.w16 However, 
in patients with severe AS, apical sparing could not predict the 
presence of cardiac amyloidosis, although an average tissue 
Doppler mitral annular S’ velocity ≤6 cm/s did provide a sensi-
tive marker.w15 Interstitial expansion associated with cardiac 
amyloidosis may be detected by CMR,49 while bone scintigraphy 
is the technique of choice for distinguishing transthyretin from 
light chain cardiac amyloidosis.w17 Current data do not demon-
strate that AVR is futile in these patients, who may still benefit 
from intervention and in whom novel amyloid therapies are now 
available.w18
The imaging techniques to interrogate myocardial function 
and disease discussed before, represent a potentially major 
advance in the assessment and management of AS. The tradi-
tional criteria for AVR are now being questioned based on our 
current understanding of pre- clinical myocardial disease in 
asymptomatic AS. Echocardiographic assessment of myocardial 
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Figure 5 Proposed schematic integrating multi- modality LV assessments in AS. The current paradigm remains one of aortic valve replacement when 
AS is severe and symptomatic, or if there is overt evidence of impaired LV function (reduced ejection fraction). Several randomised controlled trials are 
assessing early intervention in severe asymptomatic AS (orange box). Of these, only RECOVERY has been completed, demonstrating a clinical benefit 
with early intervention in a population with very severe AS, a large proportion of which were bicuspid. EVOLVED is the only trial utilising imaging 
to select a subset of asymptomatic patients for early intervention. The other trials assess if early intervention could be beneficial in this setting, 
regardless of adjunctive risk stratification tools. Echocardiography remains, and should remain, the first- line investigation to assess AS and its effect 
on the LV. However, CMR adds incremental information regarding subclinical myocardial disease (fibrosis) via tissue characterisation that cannot be 
detected with echocardiography; these pathological changes are often present before ejection fraction falls and have prognostic implications. Other 
indirect assessments of LV function in response to the fixed afterload induced by AS include exercise ECG and biomarkers such as BNP. AS, aortic 
stenosis; BNP, B- type natriuretic peptide; CMR, cardiac magnetic resonance; RECOVERY, Randomized Comparison of Early Surgery Versus Conventional 
Treatment in Very Severe Aortic Stenosis, EVOLVED, Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients 
with Severe AS; GLS, global longitudinal strain; LV, left ventricular.
deformation and CMR parameters of myocardial fibrosis offer 
clear prognostic information above and beyond valve haemo-
dynamics and LVEF alone. How the use of these novel imaging 
techniques will improve the risk stratification of patients and 
optimise the timing of AVR needs to be studied in the context 
of randomised clinical trials (figure 5). Of note, the recent land-
mark RECOVERY (Randomized Comparison of Early Surgery 
Versus Conventional Treatment in Very Severe Aortic Stenosis) 
randomised controlled trial,w19 demonstrated for the first time a 
mortality benefit with early surgical AVR in selected asymptom-
atic patients with very severe AS. The results of these important 
multicentre randomised controlled trials are highly anticipated 
and will help shape the future management paradigm of patients 
with AS.
References from w1 to w19 can be found in the online supple-
mentary material.
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